Eprosartan - A review of its use in the management of hypertension

被引：23

作者：

Robbins, GW ^{[1
]}

Scott, LJ ^{[1
]}

机构：

[1] Adis Int Ltd, Auckland 1311, New Zealand

来源：

DRUGS | 2005年 / 65卷 / 16期

关键词：

D O I：

10.2165/00003495-200565160-00012

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Sources: Medical literature published in any language since 1980 on eprosartan, identified using MEDLINE and EMBASE, supplemented by AdisBase (a proprietary database of Adis International). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug. Search strategy: MEDLINE search terms were 'eprosartan' or 'SKF-108566' and ('hypertension' or 'antihypertensive'). EMBASE and AdisBase search terms were 'eprosartan' and ('hypertension' or 'antihypertensive'). Searches were last updated 15 October 2005. Selection: Studies in patients with hypertension who received eprosartan. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic and pharmacokinetic data are also included.

引用

收藏

页码：2355 / 2377

页数：23

相关论文

共 81 条

[11] ANTIHYPERTENSIVE ACTIVITY OF THE NONPEPTIDE ANGIOTENSIN-II RECEPTOR ANTAGONIST, SK-AND-F 108566, IN RATS AND DOGS [J].

BROOKS, DP ;

FREDRICKSON, TA ;

WEINSTOCK, J ;

RUFFOLO, RR ;

EDWARDS, RM ;

GELLAI, M .

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1992, 345 (06) :673-678

[12] Pharmacology of eprosortan, an angiotensin II receptor antagonist: Exploring hypotheses from clinical data [J].

Brooks, DP ;

Ohlstein, EH ;

Ruffolo, RR .

AMERICAN HEART JOURNAL, 1999, 138 (03) :S246-S251

[13] A dose proportionality study of eprosartan in healthy male volunteers [J].

Chapelsky, MC ;

Martin, DE ;

Tenero, DM ;

Ilson, BE ;

Boike, SC ;

Etheredge, R ;

Jorkasky, DK .

JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 38 (01) :34-39

[14]

Cheng-Lai Angela, 2002, Heart Dis, V4, P54

[15]

CHEUNG BMY, 2005, J HUMAN HYPERTE 0825

[16] Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].

Chobanian, AV ;

Bakris, GL ;

Black, HR ;

Cushman, WC ;

Green, LA ;

Izzo, JL ;

Jones, DW ;

Materson, BJ ;

Oparil, S ;

Wright, JT ;

Roccella, EJ .

HYPERTENSION, 2003, 42 (06) :1206-1252

[17] Effect of eprosartan on catecholamines and peripheral haemodynamics in subjects with insulin-induced hypoglycaemia [J].

Christensen, M ;

Ibsen, H ;

Worck, R .

CLINICAL SCIENCE, 2005, 108 (02) :113-119

[18]

Cox P. J., 1996, EXP TOXICOL PATHO S2, V48, P75

[19] Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].

Dahlöf, B ;

Devereux, RB ;

Kjeldsen, SE ;

Julius, S ;

Beevers, G ;

de Faire, U ;

Fyhrquist, F ;

Ibsen, H ;

Kristiansson, K ;

Lederballe-Pedersen, O ;

Lindholm, LH ;

Nieminen, MS ;

Omvik, P ;

Oparil, S ;

Wedel, H .

LANCET, 2002, 359 (9311) :995-1003

[20] Effect of eprosartan on pulse pressure and blood pressure components in patients with isolated systolic hypertension [J].

De La Sierra, A ;

Munoz, A ;

Arcos, E ;

Lopez, JS ;

Relats, J .

BLOOD PRESSURE, 2004, 13 :5-10

← 1 2 3 4 5 6 7 8 9 →